Compare Mesoblast Limited (MESO) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Mesoblast Limited trades at $14.23 (market cap $1.75B), while T-Rex 2X Long MSTR Daily Target ETF trades at $41.03 (market cap $809.00M). The key difference: Mesoblast Limited is far larger — about 2.2× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Mesoblast Limited is more actively traded (239,027 versus 4,577,465). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and T-Rex 2X Long MSTR Daily Target ETF for 18 Days on average.
| MESO | MSTU | |
|---|---|---|
Market Cap | $1.75B | $809.00M |
Volume | 239,027 | 4,577,465 |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.96 | $451.00 |
52-Week Low | $13.19 | $14.60 |
Typical Hold Time | 14 Days | 18 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
MSTU trades at $39.54, showing minimal daily movement with a 0.23% gain. The technical outlook is bearish based on moving averages, while oscillators present a neutral stance. Recent corporate actions include a 10:1 reverse stock split and a $0.29 dividend scheduled for August 2026. News coverage highlights the ETF's leveraged nature and recent volatility concerns.
The outlook remains cautious due to the bearish technical signals and leveraged ETF structure, which amplifies volatility. Investment opportunities exist for tactical traders seeking short-term momentum, but risks include daily rebalancing effects and potential value erosion during sustained market moves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
